{"name":"MitoImmune Therapeutics","slug":"mitoimmune-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNTnliMTZNM3l5Njh2TFEzc0tLOUdSck1IaWVkVjBzMUlfRzlXelVTQTJYOV92OGZGd1NQSlBtT2FDX0J4TjhuUHNGZzNDYkw3T3J3Qk5xWUdvMnBWT041cEpKUWQzb2tYN0FXd0ZzY2hSb2xsLVY3aldueDVyNmFSeGtBdV9JTFo2Y0s3UmZ1a1pLM2VNUTVtaEhtZ3I2RWJ3eUE?oc=5","date":"2022-08-30","type":"trial","source":"globaldata.com","summary":"Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - globaldata.com","headline":"Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Upda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQUXZhcWFuNDNhV0I1SmZmSXUzRFhLakp6emJRYUtOZWNtaEdBVlAxUUduV2g5emVMTUUtLTJDOFBiMXJTUTZOSjNzYlVSNGppcjJLZUpwY0F5SS1YaWVRc3RnUS00UXV4TFRtbGVLcXNic3RHbC1INUV2emw3QnR4dUZTSkFpZkxkdlFMQ09B?oc=5","date":"2022-06-13","type":"trial","source":"globaldata.com","summary":"Oral Mucositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - globaldata.com","headline":"Oral Mucositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxPcWpUQnJnMlp5MkpVOC1jTkg1M2JvTzhrWGtGNVhKV3I1aURzNEFrcGI2XzdYa3lxb3RBZUthQTNXWlAyMWowMGw5cUl6SWVGM2dFeG0tWVZkZm5vUDE0Tm9nTHIyRjM2SEhVYTJLWDJXekhaeUFMYlM2SUg3RWdQekY3Skd3dWZDV3A2OXlSanItMjNydXp1bnI1V1pCY2VzazVsLVRrTURFVkpmZ0htWkwyNEVmSm5jMFR3RTJxUkFON29kREJRNEFGX3VRQ0FPM0JiNURTUHFOZnNBWnI0X0N6RUk5bVpiNTJiemdTU003X1dHci1sd21HbHBPWU5CdUxUVWY2MjIwWWZUNFVnVndOR0xteUhzY2Ewa09VY1NKT2hIZUE?oc=5","date":"2021-04-06","type":"regulatory","source":"BioSpace","summary":"MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer - BioSpace","headline":"MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Or","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}